Background: Long-chain fatty acids (LCFAs) cross the plasma membrane via a protein-mediated mechanism involving one or more LCFA-binding proteins. Among these, FAT/CD36 has been identified as key LCFA transporter in the heart and skeletal muscle, where it is regulated acutely and chronically by insulin. In skeletal muscle, FAT/CD36 expression and/or subcellular distribution is altered in obesity and type 2 diabetes. There is limited information as to whether the expression of this protein is also altered in subcutaneous and/or visceral adipose tissue depots in human obesity or type 2 diabetes. Objectives: To compare (a) the expression of FAT/CD36 in subcutaneous and visceral adipose tissue depots in lean, overweight, and obese individuals and in type 2 diabetics, (b) to determine whether the protein expression of FAT/CD36 in these depots is associated with the severity of insulin resistance (type 2 diabetes4obese4overweight/lean) and (c) whether FAT/CD36 protein expression in these adipose tissue depots is associated with alterations in circulating substrates and hormones. Subjects: Subjects who were undergoing abdominal surgery and who were lean (n ¼ 10; three men, seven women), overweight (n ¼ 10; three men, seven women) or obese (n ¼ 7; one man, six women), or who had been diagnosed with type 2 diabetes (n ¼ 5; one man, four women) participated in this study. Measurements: Subcutaneous and visceral adipose tissue samples, as well as blood samples, were obtained from the subjects while under general anesthesia. Adipose tissue samples were analyzed for FAT/CD36 using Western blotting. Serum samples were analyzed for glucose, insulin, FFA and leptin. BMI was also calculated. Results: Subcutaneous adipose tissue FAT/CD36 expression was upregulated by þ 58, þ 76 and þ 150% in overweight, obese and type 2 diabetics, respectively. Relative to subcutaneous adipose tissue, visceral adipose tissue FAT/CD36 expression was upregulated in lean ( þ 52%) and overweight subjects ( þ 30%). In contrast, in obese subjects and type 2 diabetics, no difference in FAT/CD36 protein expression was observed between their subcutaneous and visceral adipose tissue depots (P40.05). The subcutaneous adipose tissue FAT/CD36 expression (R ¼ 0.85) and the visceral adipose tissue FAT/CD36 expression (R ¼ 0.77) were associated with alteration in BMI and circulating glucose and insulin. Conclusions: Subcutaneous adipose tissue FAT/CD36 expression is upregulated in obesity and type 2 diabetes. As FAT/CD36 expression is not different in lean, overweight and obese subjects, and was only increased in type 2 diabetics, it appears that visceral adipose tissue FAT/CD36 may respond in a less dynamic manner to metabolic disturbances than subcutaneous adipose tissue FAT/CD36.
Introduction
It is well known that insulin resistance is observed in animal models of obesity, and in obese humans and type 2 diabetics. The increased uptake of long-chain fatty acids (LCFAs) into skeletal muscle, without a concomitant increase in its oxidation, has been linked with insulin resistance in this tissue. [1] [2] [3] [4] Owing to this, it appears that the accumulating ceramides and/or diacylglycerols can interfere with postreceptor insulin signalling. [5] [6] [7] While it had been assumed that increased rates of fatty acid uptake by muscle and other tissues were directly related to concomitant increments in circulating LCFAs, this is not necessarily the case. Despite similar circulating concentrations of LCFAs, obese individuals and type 2 diabetes patients accumulate more LCFAs within skeletal muscle, as the rate of LCFA transport into their skeletal muscle is markedly increased. 8 In the past few years, it has been established that LCFAs cross the plasma membrane via protein-mediated mechanism involving one or more LCFA-binding proteins, including a family of fatty acid transport proteins (FATP1-6, 63 kDa), plasma membrane associated fatty acid-binding protein (FABPpm, 40 kDa) and fatty acid translocase, the homolog of CD36 (FAT/CD36). In a series of studies, we have established that some of these proteins are increased in animal models of obesity 9 and type 1 diabetes, 10 as well as in human obesity and type 2 diabetes. 8 While a recent study has
shown that FATP1-null mice are resistant to diet-induced insulin resistance, 11 little else is known about how this protein is altered in selected metabolic pathologies. Similarly, the role of FABPpm in insulin resistance, if any, is unclear. Its expression seems not to be altered in skeletal muscle of obese Zucker rats 9 or in humans with obesity and type 2 diabetes. 8 In contrast, in our studies, [8] [9] [10] 12, 13 and others, 14 ,15 a prominent role has been identified for FAT/CD36 in regulating LCFA transport in the skeletal muscle, heart and adipose tissue, particularly in obesity and type 2 diabetes. FAT/CD36 is expressed ubiquitously in laboratory rats, albeit to varying extents among metabolically active tissues such as the heart, skeletal muscle, liver and adipose tissue. 9, 10, 12, 16 FAT/CD36-null mice exhibit an increased insulin sensitivity in the periphery. 17 In streptozotocininduced diabetes, an increase in plasmalemmal FAT/CD36 is observed in skeletal muscle owing to an increased expression of this protein. 10 In contrast, in obese Zucker rats 9 and in humans with obesity and type 2 diabetes, 8 
Methods
The participants (n ¼ 32) included men and women who were lean (n ¼ 10; three men, seven women), overweight (n ¼ 10; three men, seven women) or obese (n ¼ 7; one man, six women), or who had been diagnosed with type 2 diabetes (n ¼ 5; one man, four women) ( FAT/CD36 protein was determined in adipose tissue homogenates. These homogenates were prepared using a slight variation of the homogenization procedures used in skeletal muscle and removing the lipids from the protein fraction. Adipose tissue homogenization in this manner has also been carried out in our previous studies. 9, 10 Western blotting was performed as we have described previously.
9,10
For each individual and for each type of adipose tissue, the same quantity of protein (50 mg) was loaded into each well. Subcutaneous and visceral adipose tissue samples from a given individual were included in the same blot to enable direct comparison between these depots. A rat sample standard was used in each blot to permit comparisons among blots. This is the standard procedure in our laboratory.
For detection of FAT/CD36, we used the antibody MO-25, 23 as we have reported previously. 8, 9 Circulating glucose was determined as described by Bergmeyer. 24 Serum insulin (LINCO, St Charles MO, USA) and fatty acids (WAKO Chemicals, Osaka, Japan) were measured using commercially available kits. The data were analyzed using analyses of variance and a least-squares difference (LSD) post hoc test. Least-squares multiple regression was used to compare the relationship between the expression of FAT/CD36 with BMI, and circulating concentrations of selected hormones and substrates. Comparisons between men and women within groups were not performed, as in some groups, there was only one man. Data are reported as mean7s.e.m.
Results
We categorized individuals with a BMI o25 kg/m 2 as lean and those with a BMI of 25 to o30 kg/m 2 as overweight.
Individuals with a BMI430 kg/m 2 were classified as obese (Table 1) . Type 2 diabetes had been clinically diagnosed in five subjects (Table 1 ), but details of the treatment management were not made available to the investigators. The four groups differed somewhat in age. The type 2 diabetes patients were older than the overweight individuals (Table 1, Po0.05), but no other differences in age were observed among the other groups. Moreover, there were no significant correlations between age and any of the parameters measured in this study.
Glucose and insulin concentrations were higher in the type 2 diabetics than in any of the other groups (Table 1 , Po0.05). No differences in glucose, fatty acids and insulin concentrations were observed among the other groups (Table 1) . When all subjects were considered together, we observed significant correlations (Po0.05) between BMI and circulating leptin (r ¼ 0.72, Po0.05), leptin and insulin (r ¼ 0.51, Po0.05), and between insulin and glucose (r ¼ 0.79, Po0.05) ( Table 2 ).
In the subcutaneous adipose tissue, FAT/CD36 was increased in overweight ( þ 58%, Po0.05) and in obese individuals ( þ 76%, Po0.05) relative to the lean controls (Figure 1a and b) . Differences between the overweight and obese individuals did not differ (P40.05; Figure 1b) . However, in type 2 diabetes patients, the subcutaneous adipose tissue FAT/CD36 protein expression was markedly greater ( þ 150%) than in lean individuals (Po0.05), as well as in overweight and obese individuals (Po0.05; Figure 1b) .
The visceral adipose tissue FAT/CD36 expression was greater in lean ( þ 52%) and overweight ( þ 30%) individuals (Figure 1a and c) , when compared to their subcutaneous adipose tissue FAT/CD36 (Po0.05; Figure 1c ). No differences were observed between the subcutaneous and visceral adipose FAT/CD36 expression either in the obese individuals or in the type 2 diabetes patients (P40.05; Figure 1c) . Comparisons of visceral adipose tissue FAT/CD36 among groups showed that FAT/CD36 was increased in the type 2 diabetes patients relative to the obese and lean individuals (P40.05; Figure 1c) .
Correlations coefficients between selected parameters and subcutaneous and visceral adipose tissue FAT/CD36 were generally not significant ( Table 2 ). The exception was glucose, which correlated with subcutaneous adipose FAT/ CD36 (r ¼ 0.68, Po0.05) and visceral adipose FAT/CD36 (r ¼ 0.64, Po0.05).
With a multiple regression approach, it was possible to ascertain whether the FAT/CD36 protein expression in both the subcutaneous and visceral adipose tissue depots was associated with concomitant changes in a number of parameters. Strong correlations occurred when BMI, circulating glucose and insulin were used as independent factors to predict subcutaneous adipose FAT/CD36 (R ¼ 0.85, Po0.05; FAT/CD36 in human adipose tissue A Bonen et al Figure 2a ) and visceral adipose FAT/CD36 (R ¼ 0.77, Po0.05; Figure 2b ).
Discussion
We FAT/CD36 in human adipose tissue A Bonen et al expression in both the subcutaneous and visceral adipose tissue depots. In a number of studies, we [8] [9] [10] 12, 13 and others 14, 15 have
shown that the fatty acid transporter FAT/CD36 is one of the regulators of LCFA transport across the plasma membrane in a wide variety of metabolically important tissues, including adipose tissue. Thus, when the plasmalemmal content of FAT/CD36 is increased, the rate of LCFA transport across the plasma membrane is increased, [8] [9] [10] 12 and conversely, when plasmalemmal FAT/CD36 is decreased, the rate of LCFA transport is also reduced. 13,18 Although we were not able to measure the plasmalemmal FAT/CD36 in subcutaneous and visceral adipose tissue in the present study, we have previously shown that alterations in the expression of this protein are accompanied by concomitant changes in their plasmalemmal content in both skeletal muscle 10, 13 and adipose tissue. 9 Moreover, in our animal studies, the increase in FAT/CD36 protein expression is associated with an increased rate palmitate transport across the plasma membrane of adipose tissue. 9 Thus, it seems reasonable to assume that the increase in FAT/CD36 in subcutaneous adipose tissue of overweight and obese individuals reflects a greater capacity to flux LCFAs across the plasma membrane. LCFA transport rates would presumably be even more pronounced in type 2 diabetes patients, who demonstrated the greatest increase in the expression of FAT/CD36 in both the subcutaneous and visceral adipose tissue depots. Two previous studies have examined FAT/CD36 protein expression in subcutaneous, but not visceral adipose tissue in humans. Recent studies by Gertow et al. 25 observed that FAT/ CD36 mRNA expression in adipose tissue was correlated with measures of obesity, although there can be quite a poor relationship between LCFA transporter mRNA and protein expression (e.g. Luiken et al.
9
). In another study, Fisher et al. 20 reported that there was no difference in subcutaneous adipose tissue FAT/CD36 protein when lean (BMI ¼ 23 kg/ m 2 ) and obese (BMI ¼ 42 kg/m 2 ) individuals were compared. However, this study is difficult to interpret as the quality of the Western blots shown is far from ideal, and the actin expression differed threefold between lean and obese individuals, possibly indicating unequal loading of the samples. However, when the data are expressed relative to actin, FAT/CD36 protein expression was far greater in the obese individuals. There was also a 40% reduction in FAT/ CD36 protein subcutaneous adipose tissue after a 25% weight loss (À28.6 kg) over a 2-year period. 20 Despite the limitations of various studies, our present study and others 20, 25 indicate that FAT/CD36 is upregulated in subcutaneous adipose tissue of obese individuals. Although increments in visceral adipose tissue mass has in many studies been associated with insulin resistance, FAT/ CD36 expression in visceral adipose tissue did not differ between lean and obese subjects, many of whom are likely to be insulin resistant, although direct measures of insulin resistance were not obtained. FAT/CD36 expression may be less plastic in the visceral adipose tissue. In this depot, compared to subcutaneous adipose tissue, FAT/CD36 expression was already 30-50% greater in lean and overweight individuals, whereas no differences in FAT/CD36 protein levels were found between the subcutaneous and visceral adipose tissue depots in obese and type 2 diabetes patients. These data may suggest that under normal circumstances (and on a per mg tissue protein basis), visceral adipose tissue has a greater FAT/CD36-mediated capacity to flux LCFAs across the plasma membrane compared to subcutaneous adipose tissue, in lean and overweight subjects, whereas in obese individuals and type 2 diabetes patients, FAT/CD36-mediated flux is similar in subcutaneous and visceral adipose tissue.
The present study is based on the same individuals in whom we 8 Based on the multiple regression analyses, it appeared that the circulating glucose and insulin concentrations, as well as BMI, were key factors associated with the FAT/CD36 protein expression in adipose tissues. We recognize that the multiple regression analyses are based on few subjects and there is colinearity in the insulin and glucose data. With these limitations in mind, we speculate that the substrate hormone milieu is involved in regulating the expression of FAT/CD36. However, it is not known whether chronically increased insulin and/or glucose induce the expression of FAT/CD36 in adipose tissue in humans. In animal studies, circulating glucose does not appear to induce FAT/CD36 expression. For example, in hypoinsulinemic-hyperglycemic animals, FAT/CD36 protein expression in adipose tissue was not altered. 10 However, a case for the induction of FAT/CD36
by insulin can be made, based on studies in both humans and animals. Higher insulin concentrations in obese compared to lean Zucker rats were associated with an increased FAT/CD36 protein expression in adipose tissue, whereas basal glucose concentrations did not differ between these animals. 9 In addition, we have recently shown that insulin rapidly induces the expression of FAT/CD36 in cardiac myocytes and in the heart. 26 In humans, FAT/CD36 mRNA is increased in muscle during a hyperinsulinemic-euglycemic clamp, 27 and FAT/CD36 mRNA and insulin are correlated. 25 Thus, a circumstantial case can be made implicating increased concentrations of insulin in upregulating the expression of adipose tissue FAT/CD36. However, in the present study, circulating glucose concentrations (r ¼ 0.68 and 0.64), rather than circulating insulin concentrations FAT/CD36 in human adipose tissue A Bonen et al (r ¼ 0.31 and 0.26), were correlated with FAT/CD36 expression in subcutaneous and visceral adipose tissue. Thus, at a mechanistic level, it needs to be resolved whether in humans it is the circulating insulin and/or glucose that induce FAT/ CD36 protein expression in adipose tissue. The multiple regression correlation suggests that FAT/CD36 expression is regulated by both glucose and insulin, perhaps in a synergistic manner. This is also indicated by the data in the type 2 diabetes patients, who exhibited the greatest FAT/ CD36 protein expression and who were also characterized with the largest concentrations of both circulating glucose and insulin. There were several limitations in this study. First, details of the treatment management in type 2 diabetes patients were not made available to the investigators. Thus, in some individuals, the upregulation of FAT/CD36 could have been owing to treatment, if they were being treated with thiazolidinediones. 28 Second, we obtained blood samples from the subjects while under general anesthesia. It is well known that with general anesthesia, there are changes in circulating substrates and hormones. [29] [30] [31] This may account for the elevated fatty acids in the present study, as has been noted previously. 29 The prolonged period of fasting (16-18 h) before surgery was likely also a contributing factor. In the present study, glucose concentrations appeared to be somewhat increased in lean and overweight subjects, as the glucose concentrations were similar to those observed during general anesthesia in other studies. 30, 31 Nevertheless, insulin resistance was evident in the type 2 diabetes patients, as both their glucose and insulin concentrations were greater than in the other groups. In summary, we have shown that FAT/CD36 expression is increased in subcutaneous adipose tissue of overweight and obese individuals, and that the expression of this protein is further increased in subcutaneous adipose tissue of type 2 diabetes patients. No differences in visceral adipose tissue FAT/CD36 were observed among three groups (lean, overweight, obese) while this protein was overexpressed in the type 2 diabetes patients. FAT/CD36 expression in both subcutaneous and visceral adipose tissue was correlated (multiple regression) with BMI and circulating glucose and insulin.
